AU2010204552B2 - New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein - Google Patents

New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein Download PDF

Info

Publication number
AU2010204552B2
AU2010204552B2 AU2010204552A AU2010204552A AU2010204552B2 AU 2010204552 B2 AU2010204552 B2 AU 2010204552B2 AU 2010204552 A AU2010204552 A AU 2010204552A AU 2010204552 A AU2010204552 A AU 2010204552A AU 2010204552 B2 AU2010204552 B2 AU 2010204552B2
Authority
AU
Australia
Prior art keywords
neug
neutropenia
subject
dose
pegfilgrastim
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010204552A
Other languages
English (en)
Other versions
AU2010204552A1 (en
Inventor
Adam Carr Bell
Jason Benjamin Bock
Jeffrey Herpst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of AU2010204552A1 publication Critical patent/AU2010204552A1/en
Application granted granted Critical
Publication of AU2010204552B2 publication Critical patent/AU2010204552B2/en
Priority to AU2014208224A priority Critical patent/AU2014208224A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2010204552A 2009-01-16 2010-01-15 New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein Ceased AU2010204552B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2014208224A AU2014208224A1 (en) 2009-01-16 2014-07-30 New Stable Formulations of Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor Fusion Protein

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14544009P 2009-01-16 2009-01-16
US14543609P 2009-01-16 2009-01-16
US61/145,436 2009-01-16
US61/145,440 2009-01-16
PCT/US2010/021241 WO2010083439A2 (en) 2009-01-16 2010-01-15 Recombinant human albumin-human granulocyte colony stimulating factor for the prevention of neutropenia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2014208224A Division AU2014208224A1 (en) 2009-01-16 2014-07-30 New Stable Formulations of Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor Fusion Protein

Publications (2)

Publication Number Publication Date
AU2010204552A1 AU2010204552A1 (en) 2011-08-04
AU2010204552B2 true AU2010204552B2 (en) 2014-05-01

Family

ID=42260335

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2010204552A Ceased AU2010204552B2 (en) 2009-01-16 2010-01-15 New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
AU2010204547A Ceased AU2010204547B2 (en) 2009-01-16 2010-01-15 New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2010204547A Ceased AU2010204547B2 (en) 2009-01-16 2010-01-15 New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein

Country Status (16)

Country Link
US (4) US8323634B2 (enExample)
EP (2) EP2387419A2 (enExample)
JP (2) JP2012515222A (enExample)
KR (2) KR20110132326A (enExample)
CN (2) CN102395379B (enExample)
AU (2) AU2010204552B2 (enExample)
BR (2) BRPI1004940A2 (enExample)
CA (2) CA2749786A1 (enExample)
EA (2) EA201190079A1 (enExample)
IL (2) IL214052A0 (enExample)
MX (2) MX2011007583A (enExample)
NZ (2) NZ594055A (enExample)
SG (3) SG196821A1 (enExample)
UA (2) UA103221C2 (enExample)
WO (2) WO2010083439A2 (enExample)
ZA (1) ZA201105171B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011007583A (es) * 2009-01-16 2011-12-14 Teva Pharma Nuevas formulaciones estables de proteina de fusion recombinante de albumina humana-factor humano de estimulacion de colonias de granulocitos.
EP2384759A1 (en) 2010-05-06 2011-11-09 Suomen Punainen Risti Veripalvelu Sulphated hyaluronic acid in combination with G-CSF for use in mobilising blood stem cells
ES2545411T5 (es) * 2010-06-07 2024-04-05 Amgen Inc Dispositivo de administración de fármaco
CN102628869B (zh) * 2012-04-19 2014-04-02 上海蓝怡科技有限公司 提高甲胎蛋白抗体冻干稳定性的制剂
AR094481A1 (es) * 2013-01-15 2015-08-05 Teva Pharma Formulaciones de albu-bche (albúmina-butirilcolinesterasa), preparación y sus usos
US20140271538A1 (en) 2013-03-15 2014-09-18 Teva Pharmaceutical Industries Ltd. Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor for the Prevention of Neutropenia in Pediatric Patients
MA40904A (fr) * 2014-11-03 2017-09-12 Hygeia Tech Inc Compositions d'ester de phorbol et procédés pour traiter ou réduire la durée d'une cytopénie
SG10202008673WA (en) 2015-03-06 2020-10-29 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation
BE1023343B1 (nl) * 2015-05-20 2017-02-09 Mycartis Nv Opslagbuffer
US10155748B2 (en) 2015-07-13 2018-12-18 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
US11020455B2 (en) * 2015-07-30 2021-06-01 Endor Technologies, S.L Colony stimulating factor for use in pancreatic or colon cancer treatment
JP2019511565A (ja) 2016-02-08 2019-04-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド ツカレゾールまたはそのアナログを含む組成物
AU2017278245B2 (en) 2016-06-06 2022-09-15 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing neutropenia
CN106222221A (zh) * 2016-08-05 2016-12-14 山东科兴生物制品有限公司 制备重组人粒细胞刺激因子原液的纯化方法
ES2985905T3 (es) 2016-11-22 2024-11-07 Lts Device Tech Ltd Aparato para suministrar una sustancia terapéutica
EP3565812B1 (en) 2017-01-06 2023-12-27 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
KR20240110997A (ko) 2017-02-01 2024-07-16 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법
WO2018187786A1 (en) * 2017-04-07 2018-10-11 La Jolla Institute For Allergy And Immunology Unipotent neutrophil progenitor cells, methods of preparation, and uses thereof
CN109420159A (zh) * 2017-08-23 2019-03-05 江苏泰康生物医药有限公司 一种重组蛋白药物的新型稳定制剂
EP3743074A4 (en) 2018-01-24 2021-12-15 Beyondspring Pharmaceuticals Inc. COMPOSITION AND METHOD FOR REDUCING THROMBOCYTOPENIA BY THE ADMINISTRATION OF PLINABULINE
CA3089391A1 (en) * 2018-02-01 2019-08-08 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a g-csf agent
US11583633B2 (en) 2018-04-03 2023-02-21 Amgen Inc. Systems and methods for delayed drug delivery
US11357909B2 (en) 2018-10-05 2022-06-14 Eitan Medical Ltd. Triggering sequence
CN111383745A (zh) * 2018-12-29 2020-07-07 医渡云（北京）技术有限公司 计算机数据处理方法、装置、存储介质及设备
US11684655B2 (en) * 2019-05-31 2023-06-27 Spectrum Pharmaceuticals, Inc. Methods of treating neutorpenia using G-CSF protein complex
US11267858B2 (en) * 2019-05-31 2022-03-08 Spectrum Pharmaceuticals, Inc. Methods of treatment using G-CSF protein complex
CN112316120A (zh) * 2019-08-05 2021-02-05 天津派格生物技术有限公司 使用低动员型g-csf有效且安全治疗粒细胞减少症的方法
JP2023505506A (ja) * 2019-12-05 2023-02-09 ハンミ ファーマシューティカルズ カンパニー リミテッド 化学療法または放射線療法で誘導された好中球減少症を治療する方法
KR102485892B1 (ko) * 2020-04-09 2023-01-09 주식회사 에이프릴바이오 고양이 과립구 집락 자극인자 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도
CN111751552B (zh) * 2020-06-18 2022-09-16 广州市伊川生物科技有限公司 一种缺血修饰白蛋白测定试剂盒及其使用方法
KR102375269B1 (ko) * 2021-01-27 2022-03-17 한미약품 주식회사 단백질 액상 제제 및 이의 제조방법
WO2022216908A1 (en) 2021-04-09 2022-10-13 Beyondspring Pharmaceuticals, Inc. Therapeutic compositions and methods for treating tumors
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015199A1 (fr) * 1992-01-31 1993-08-05 Rhone-Poulenc Rorer S.A. Nouveaux polypeptides biologiquement actifs, leur preparation et composition pharmaceutique les contenant
US5665863A (en) * 1992-01-31 1997-09-09 Rhone-Poulenc Rorer S.A. Polypeptides having granulocyte colony stimulating activity, their preparation and pharmaceutical compositions containing them
WO2003076567A2 (en) * 2002-03-05 2003-09-18 Eli Lilly And Company Heterologous g-csf fusion proteins
US20080153751A1 (en) * 2001-12-21 2008-06-26 Human Genome Sciences, Inc. Albumin Fusion Proteins

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0286424B1 (en) * 1987-04-09 1994-03-16 Delta Biotechnology Limited Yeast vector
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
DE19549232C2 (de) * 1995-12-20 1998-05-20 Boehringer Mannheim Gmbh Verwendung von G-CSF in Kombination mit einem Chemotherapeutikum bei der Behandlung von Erkrankungen, die eine periphere Stammzelltransplantation erfordern
US7321023B2 (en) * 1997-11-07 2008-01-22 Incyte Corporation SP16 protein
US6776983B1 (en) * 1998-03-06 2004-08-17 Chugai Seiyaku Kabushiki Kaisha Protein free formulations
US6831158B2 (en) * 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
EP1274720A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc FUSION PROTEINS CONTAINING ALBUMIN
EP1399131A2 (en) * 2001-06-08 2004-03-24 Powderject Vaccines, Inc. Spray freeze-dried compositions
CN1241946C (zh) * 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
CA2513213C (en) * 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
WO2004082640A2 (en) 2003-03-19 2004-09-30 New Century Pharmaceuticals, Inc. Human serum albumin conjugates with therapeutic compounds
US6972332B1 (en) * 2004-05-20 2005-12-06 Acura Pharmaceuticals, Inc. Process for the production of opiates
JP2009504157A (ja) 2005-08-12 2009-02-05 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合タンパク質
US8800782B2 (en) * 2006-04-13 2014-08-12 Wix Filtration Corp Llc Filter element
JP2008146587A (ja) * 2006-12-13 2008-06-26 Sony Corp 表示装置、表示プログラム、表示方法、画像提供装置、画像提供プログラム、画像提供方法及び記録媒体
MX2011007583A (es) 2009-01-16 2011-12-14 Teva Pharma Nuevas formulaciones estables de proteina de fusion recombinante de albumina humana-factor humano de estimulacion de colonias de granulocitos.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015199A1 (fr) * 1992-01-31 1993-08-05 Rhone-Poulenc Rorer S.A. Nouveaux polypeptides biologiquement actifs, leur preparation et composition pharmaceutique les contenant
US5665863A (en) * 1992-01-31 1997-09-09 Rhone-Poulenc Rorer S.A. Polypeptides having granulocyte colony stimulating activity, their preparation and pharmaceutical compositions containing them
US20080153751A1 (en) * 2001-12-21 2008-06-26 Human Genome Sciences, Inc. Albumin Fusion Proteins
WO2003076567A2 (en) * 2002-03-05 2003-09-18 Eli Lilly And Company Heterologous g-csf fusion proteins

Also Published As

Publication number Publication date
AU2010204547A1 (en) 2011-07-28
KR20110132326A (ko) 2011-12-07
KR20110132327A (ko) 2011-12-07
JP2012515221A (ja) 2012-07-05
SG172940A1 (en) 2011-08-29
US20100297062A1 (en) 2010-11-25
UA103221C2 (uk) 2013-09-25
BRPI1004940A2 (pt) 2018-06-19
MX2011007582A (es) 2011-12-14
NZ594055A (en) 2013-03-28
US8323634B2 (en) 2012-12-04
ZA201105171B (en) 2015-12-23
US20130129669A1 (en) 2013-05-23
JP5753095B2 (ja) 2015-07-22
WO2010083434A2 (en) 2010-07-22
IL214051A0 (en) 2011-08-31
NZ594056A (en) 2013-03-28
CN102378635A (zh) 2012-03-14
US20100227818A1 (en) 2010-09-09
UA105201C2 (uk) 2014-04-25
CN102395379B (zh) 2015-07-22
EA023344B1 (ru) 2016-05-31
CA2749802C (en) 2016-08-23
SG172941A1 (en) 2011-08-29
EP2387420A2 (en) 2011-11-23
SG196821A1 (en) 2014-02-13
EA201190079A1 (ru) 2013-02-28
IL214052A0 (en) 2011-08-31
CA2749786A1 (en) 2010-07-22
WO2010083434A3 (en) 2010-09-10
MX2011007583A (es) 2011-12-14
CA2749802A1 (en) 2010-07-22
WO2010083439A2 (en) 2010-07-22
WO2010083439A3 (en) 2010-09-10
US8993519B2 (en) 2015-03-31
BRPI1005159A2 (pt) 2018-04-03
AU2010204552A1 (en) 2011-08-04
EP2387419A2 (en) 2011-11-23
EA201190080A1 (ru) 2014-03-31
AU2010204547B2 (en) 2014-01-23
JP2012515222A (ja) 2012-07-05
US20150202268A1 (en) 2015-07-23
CN102395379A (zh) 2012-03-28

Similar Documents

Publication Publication Date Title
CA2749802C (en) New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
CN105209054A (zh) 使用白细胞介素-10治疗疾病和病症的方法
JP2012046552A (ja) 腎細胞ガンを処置するための方法
EP3063275A1 (en) Therapeutic nuclease-albumin fusions and methods
US20220370563A1 (en) Methods of administration of il-2 receptor agonists
CN107106655A (zh) 使用白细胞介素‑10治疗疾病和病症的方法
KR20230004655A (ko) 이종이량체 인간 인터류킨-15(hetIL-15)의 약제학적 조성물 및 약제학적 제품
WO2015138638A1 (en) Long acting trail receptor agonists for treatment of autoimmune diseases
US20240350647A1 (en) Sting sensitizing agents
AU2014208224A1 (en) New Stable Formulations of Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor Fusion Protein
AU2014202190B2 (en) New Stable Formulations of Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor Fusion Protein
US20060269514A1 (en) Methods and compositions for the modulation of immune responses and cancer diseases
US20140271538A1 (en) Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor for the Prevention of Neutropenia in Pediatric Patients
WO2023097111A2 (en) Methods and compositions for treating calcinosis associated conditions
CN117683140A (zh) 肿瘤靶向的以白介素2为活性成分的融合蛋白型药物前体
Powers et al. Alexandra Lerchner3, Martin Schlapschy4, Rajiv Datar5, Uli Binder3, Carl K. Edwards, III5, Arne Skerra4, and Charles A. Dinarello1, 2
WO2010008561A2 (en) Methods and compositions for protecting against cytotoxic therapy
KR20130010477A (ko) Ｓｐａｒｃ 혈관형성 영역과 사용방법

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired